MA45727A - Analogues de l'insuline - Google Patents

Analogues de l'insuline

Info

Publication number
MA45727A
MA45727A MA045727A MA45727A MA45727A MA 45727 A MA45727 A MA 45727A MA 045727 A MA045727 A MA 045727A MA 45727 A MA45727 A MA 45727A MA 45727 A MA45727 A MA 45727A
Authority
MA
Morocco
Prior art keywords
insulin analogues
analogues
insulin
Prior art date
Application number
MA045727A
Other languages
English (en)
Inventor
Olivera M Baldomero
Danny Hung-Chieh Chou
Michael Colin Lawrence
John Gerbrandt Tasman Menting
Helena Safavi-Hemami
Brian Smith
Original Assignee
Walter & Eliza Hall Inst Medical Res
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Walter & Eliza Hall Inst Medical Res, Univ Utah Res Found filed Critical Walter & Eliza Hall Inst Medical Res
Publication of MA45727A publication Critical patent/MA45727A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
MA045727A 2016-07-22 2017-07-21 Analogues de l'insuline MA45727A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
US201762483118P 2017-04-07 2017-04-07

Publications (1)

Publication Number Publication Date
MA45727A true MA45727A (fr) 2019-05-29

Family

ID=65524551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045727A MA45727A (fr) 2016-07-22 2017-07-21 Analogues de l'insuline

Country Status (15)

Country Link
US (2) US11248034B2 (fr)
EP (1) EP3487876A4 (fr)
JP (2) JP7143275B2 (fr)
KR (2) KR20230070049A (fr)
CN (2) CN110072884B (fr)
AU (1) AU2021269301B2 (fr)
BR (1) BR112019000991A2 (fr)
CL (1) CL2019000159A1 (fr)
CR (1) CR20190096A (fr)
IL (1) IL264330B2 (fr)
MA (1) MA45727A (fr)
MX (1) MX2019000829A (fr)
RU (1) RU2769476C2 (fr)
SG (1) SG11201900181RA (fr)
ZA (1) ZA201901095B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7143275B2 (ja) 2016-07-22 2022-09-28 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション インスリンアナログ
JP7186400B2 (ja) * 2016-08-30 2022-12-09 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ゲノム的に再コードした生物におけるセレノ-生物製剤の製造
EP4326311A1 (fr) * 2021-04-22 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Peptides c-alpha d'insuline humaine et méthodes d'utilisation
JP2025517836A (ja) * 2022-05-26 2025-06-12 トランスダーマル デリバリー ソリューションズ コーポレーション(ディー.ビー.エー.ハイポスプレー ファーマ) 経皮インスリン製剤およびその利用法
JP7838098B2 (ja) 2022-05-31 2026-03-31 エルジー エナジー ソリューション リミテッド 高分子固体電解質及びその製造方法
WO2024218715A1 (fr) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Milieu de culture à base d'hydrolysat de protéines et leur procédé de préparation
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104305C1 (ru) * 1986-08-29 1998-02-10 Ново Нордиск А.С. Аналоги инсулина человека, способ их получения, раствор для инъекций
WO2005095443A1 (fr) * 2004-03-31 2005-10-13 Cardio Incorporated Système d'administration médicamenteuse utilisant un peptide modifié
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
US8575096B2 (en) * 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
US9200053B2 (en) * 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
EP2318432B1 (fr) 2008-07-31 2015-09-02 Case Western Reserve University Insuline stabilisée par de l'halogène
EP2376531A1 (fr) * 2008-12-09 2011-10-19 Novo Nordisk A/S Nouveaux analogues de l'insuline
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
US20130022592A1 (en) * 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
EP2948166B1 (fr) * 2013-01-22 2020-12-09 Case Western Reserve University Analogues d'insuline tronqués à leur extrémité n-terminale
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン‐インクレチン複合物
JP2016516728A (ja) * 2013-03-15 2016-06-09 ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University 第2部位インスリン類似体
WO2014201370A1 (fr) * 2013-06-14 2014-12-18 President And Fellows Of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
WO2018014091A1 (fr) 2016-07-22 2018-01-25 University Of Utah Research Foundation Analogues de l'insuline
JP7143275B2 (ja) 2016-07-22 2022-09-28 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション インスリンアナログ
WO2021081335A1 (fr) * 2019-10-24 2021-04-29 University Of Utah Research Foundation Nouvelle mini-insuline à chaîne a c-terminale étendue

Also Published As

Publication number Publication date
SG11201900181RA (en) 2019-02-27
IL264330B2 (en) 2024-05-01
AU2021269301A1 (en) 2021-12-09
US12410228B2 (en) 2025-09-09
US20190241640A1 (en) 2019-08-08
CN110072884B (zh) 2023-07-28
ZA201901095B (en) 2022-04-28
KR20230070049A (ko) 2023-05-19
IL264330A (fr) 2019-03-31
CR20190096A (es) 2019-09-16
JP2019534843A (ja) 2019-12-05
RU2769476C2 (ru) 2022-04-01
JP7143275B2 (ja) 2022-09-28
CN116874584A (zh) 2023-10-13
IL264330B1 (en) 2024-01-01
AU2021269301B2 (en) 2023-12-21
RU2019100497A (ru) 2020-08-24
EP3487876A4 (fr) 2020-02-19
KR102529353B1 (ko) 2023-05-04
BR112019000991A2 (pt) 2019-07-02
RU2019100497A3 (fr) 2021-05-11
US11248034B2 (en) 2022-02-15
EP3487876A1 (fr) 2019-05-29
CN110072884A (zh) 2019-07-30
US20220340636A1 (en) 2022-10-27
CL2019000159A1 (es) 2019-08-16
JP2022191233A (ja) 2022-12-27
KR20190039719A (ko) 2019-04-15
MX2019000829A (es) 2019-08-29
NZ750355A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
MA42036A (fr) Analogues nucléosidiques 5'-substitués
MA46180A (fr) Analogues de l'amyline
ME03384B (fr) Compositions d'insuline à action rapide
MA41188A (fr) Compositions d'insuline à action rapide
DK3490991T3 (da) Coelenterazine analogues
MA42701A (fr) Compositions d'insuline à action rapide
EP3487876A4 (fr) Analogues de l'insuline
EP3394198A4 (fr) Adhésif thermofusible durcissable à l'humidité
EP2948469A4 (fr) Polypeptide c ur d'hépatite b stabilisé
EP2968473A4 (fr) Analogues d'insuline de site 2
EP3338446A4 (fr) Projections d'image
EP3463413A4 (fr) Agonistes partiels du récepteur de l'insuline
UA32431S (uk) Стрем'янка
FR3045273B1 (fr) Piquet d'extremite
EP3350199A4 (fr) Peptides cycliques d'oxydiazole
ITUB201551290U1 (it) Ovie' oviel
UA31879S (uk) Стіл-трансформер «маgnат»
UA31878S (uk) Стіл-трансформер «sріdеr»
UA33007S (uk) Олівець столярний
ITUA20163709A1 (it) "presentosa3d"
UA31292S (uk) Логотип «маланка»
UA32038S (uk) Браслет «мірстан»
UA31772S (uk) Етикетка «воронеж»
UA31997S (uk) Етикетка «карпатська»
UA32536S (uk) Логотип «нямушка»